CareLit · DOI-Nachweis · Aktuelle Rheumatologie
Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)
DOI 10.1055/a-2403-2896
Bibliografische Angaben
Nachweis in CareLit
Autor:innenAli Ekin, Salim Misirci, Nihal Lermi, Nagehan Dik Kutlu, Belkis Nihan Coskun, Burcu Yagız, Ediz Dalkılıç, Yavuz Pehlivan
ZeitschriftAktuelle Rheumatologie
Ausgabe01/2025
Jahrgang / SeitenJg. 50 · S. 71-82
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Backgorund Rituximab is an anti-CD20 monoclonal antibody used in the treatment of rheumatoid arthritis. The molecule CT -P10 is a biosimilar of rituximab used in rheumatoid arthritis and has the same safety and efficacy. Material and methods The aim of our study was to investigate whether drug efficacy decreases after the mandatory switch from originator rituximab to biosimilar rituximab, whether there is a…
Zitieren
Zitierempfehlung
Ali Ekin, Salim Misirci, Nihal Lermi, Nagehan Dik Kutlu, Belkis Nihan Coskun, Burcu Yagız, Ediz Dalkılıç, Yavuz Pehlivan (2025) Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10). Aktuelle Rheumatologie, 50 (01), 71-82. https://doi.org/10.1055/a-2403-2896
Mit CareLit weiterarbeiten